Cargando…

Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma

INTRODUCTION: Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, and the main treatment for UM is currently surgery and plaque brachytherapy. UM is highly susceptible to metastasis, which eventually occurs in nearly half of all patients; once metastasis occurs, pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yuanyuan, Cai, Jiayang, Ye, Meng, Mou, Qianxue, Zhao, Bowen, Sun, Qian, Lou, Xiaotong, Zhang, Hong, Zhao, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709208/
https://www.ncbi.nlm.nih.gov/pubmed/36466923
http://dx.doi.org/10.3389/fimmu.2022.1037128
_version_ 1784841097450618880
author Hu, Yuanyuan
Cai, Jiayang
Ye, Meng
Mou, Qianxue
Zhao, Bowen
Sun, Qian
Lou, Xiaotong
Zhang, Hong
Zhao, Yin
author_facet Hu, Yuanyuan
Cai, Jiayang
Ye, Meng
Mou, Qianxue
Zhao, Bowen
Sun, Qian
Lou, Xiaotong
Zhang, Hong
Zhao, Yin
author_sort Hu, Yuanyuan
collection PubMed
description INTRODUCTION: Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, and the main treatment for UM is currently surgery and plaque brachytherapy. UM is highly susceptible to metastasis, which eventually occurs in nearly half of all patients; once metastasis occurs, patients have a poor prognosis and the condition is difficult to treat. Therefore, the identification of new and effective UM biomarkers is vital for the application of therapeutic strategies. Immunogenic cell death (ICD) is a type of regulatory cell death that activates adaptive immune responses and generates long-term immunological memory. ICD can promote antitumor immunity, which may be a potential immunotherapeutic strategy for UM. METHODS: The data of UM from the Cancer Genome Atlas (TCGA) was used as a training set and the data from Gene Expression Omnibus (GEO) was used as a validation set. To determine the expression pattern of ICD-related genes in UM, survival analysis and difference analysis was conducted. The ICD-related risk signature was constructed by employing the least absolute shrinkage and selection operator (LASSO) Cox regression. Subsequently, immune profile and somatic mutation analysis were performed. In addition, cell experiments were performed to verify the role of immunogenic cell death-related genes in UM. RESULTS: In this study, we analyzed the relationship between ICD-related gene expression and UM patient prognosis, somatic mutations, and the tumor immune microenvironment. Importantly, we constructed a 5-gene ICD-related risk signature and confirmed it as a novel prognostic biomarker in UM patients. We found that the high-risk group had more immune cell infiltration and a worse prognosis than the low-risk group. In cellular experiments, we confirmed the high expression of FOXP3 inMUM2B andOCM-1A cell lines and that knockdown of FOXP3 markedly inhibited the proliferation of UM tumor cells. DISCUSSION: ICD-related genes play a critical role in the tumor immune microenvironment. Our results may contribute to the development of effective immunotherapies.
format Online
Article
Text
id pubmed-9709208
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97092082022-12-01 Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma Hu, Yuanyuan Cai, Jiayang Ye, Meng Mou, Qianxue Zhao, Bowen Sun, Qian Lou, Xiaotong Zhang, Hong Zhao, Yin Front Immunol Immunology INTRODUCTION: Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, and the main treatment for UM is currently surgery and plaque brachytherapy. UM is highly susceptible to metastasis, which eventually occurs in nearly half of all patients; once metastasis occurs, patients have a poor prognosis and the condition is difficult to treat. Therefore, the identification of new and effective UM biomarkers is vital for the application of therapeutic strategies. Immunogenic cell death (ICD) is a type of regulatory cell death that activates adaptive immune responses and generates long-term immunological memory. ICD can promote antitumor immunity, which may be a potential immunotherapeutic strategy for UM. METHODS: The data of UM from the Cancer Genome Atlas (TCGA) was used as a training set and the data from Gene Expression Omnibus (GEO) was used as a validation set. To determine the expression pattern of ICD-related genes in UM, survival analysis and difference analysis was conducted. The ICD-related risk signature was constructed by employing the least absolute shrinkage and selection operator (LASSO) Cox regression. Subsequently, immune profile and somatic mutation analysis were performed. In addition, cell experiments were performed to verify the role of immunogenic cell death-related genes in UM. RESULTS: In this study, we analyzed the relationship between ICD-related gene expression and UM patient prognosis, somatic mutations, and the tumor immune microenvironment. Importantly, we constructed a 5-gene ICD-related risk signature and confirmed it as a novel prognostic biomarker in UM patients. We found that the high-risk group had more immune cell infiltration and a worse prognosis than the low-risk group. In cellular experiments, we confirmed the high expression of FOXP3 inMUM2B andOCM-1A cell lines and that knockdown of FOXP3 markedly inhibited the proliferation of UM tumor cells. DISCUSSION: ICD-related genes play a critical role in the tumor immune microenvironment. Our results may contribute to the development of effective immunotherapies. Frontiers Media S.A. 2022-11-16 /pmc/articles/PMC9709208/ /pubmed/36466923 http://dx.doi.org/10.3389/fimmu.2022.1037128 Text en Copyright © 2022 Hu, Cai, Ye, Mou, Zhao, Sun, Lou, Zhang and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hu, Yuanyuan
Cai, Jiayang
Ye, Meng
Mou, Qianxue
Zhao, Bowen
Sun, Qian
Lou, Xiaotong
Zhang, Hong
Zhao, Yin
Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
title Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
title_full Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
title_fullStr Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
title_full_unstemmed Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
title_short Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
title_sort development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709208/
https://www.ncbi.nlm.nih.gov/pubmed/36466923
http://dx.doi.org/10.3389/fimmu.2022.1037128
work_keys_str_mv AT huyuanyuan developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT caijiayang developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT yemeng developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT mouqianxue developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT zhaobowen developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT sunqian developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT louxiaotong developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT zhanghong developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma
AT zhaoyin developmentandvalidationofimmunogeniccelldeathrelatedsignatureforpredictingtheprognosisandimmunelandscapeofuvealmelanoma